Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Stuart M. Harding"'
Autor:
Scott Osur, Stuart M. Harding, Kenneth G. Faulkner, Susan P. Duke, James P. Kemp, Courtney Crim, Nancy Herje, Stephen Shrewsbury
Publikováno v:
Mayo Clinic Proceedings. 79:458-466
Objective To evaluate the effects of treatment with fluticasone propionate vs placebo on bone, hypothalamic-pituitary-adrenal (HPA) axis function, and the eyes in patients with asthma. Patients and Methods This randomized, double-blind, placebo-contr
Autor:
Stuart M. Harding, Jill P. Wolford, Albert Finn, Robert A. Nathan, Robert Jones, James T. Li, J. Ellen Payne
Publikováno v:
Chest. 118:296-302
Study objective: This dose-ranging study evaluated the clinical efficacy and safety of inhaled fluticasone propionate administered once daily via a multidose powder inhaler in patients with moderate asthma (FEV1, 45 to 75% predicted). Materials and m
Autor:
Jeffery Adelglass, Patrick D. Wire, Richard ZuWallack, Dennis P. Clifford, Stuart M. Harding, Melissa A. Faris, Susan P. Duke
Publikováno v:
Chest. 118:303-312
Objective To evaluate the efficacy and safety of fluticasone propionate administered as a once-daily or twice-daily regimen over a period of 1 year to patients with moderate asthma. Design Double-blind, randomized, parallel group, and placebo-control
Autor:
Stuart M. Harding, Nancy Herje, James T.C. Li, Tushar Shah, Paul Chervinsky, Abbas G. Hamedani, Donald J Kellerman, Kenneth G. Faulkner, Stephen C. Weisberg, Linda B. Ford
Publikováno v:
Journal of Allergy and Clinical Immunology. 103:1062-1068
Background: Although inhaled corticosteroids are widely used for the treatment of inflammation in asthma, prospective, long-term, placebo-controlled trials characterizing their systemic safety with chronic use are lacking. Objective: This study was d
Autor:
Tushar Shah, Jill P. Wolford, Bennett P. deBoisblanc, Abbas G. Hamedani, William Busse, H. Nelson, Michael Noonan, Puneet Mahajan, Stuart M. Harding, D.Robert Webb, William E. Berger
Publikováno v:
Journal of Allergy and Clinical Immunology. 103:267-275
Background: Many patients with severe asthma are dependent on oral corticosteroids for maintenance control of their disease. Treatments that allow patients to be weaned off oral corticosteroids may help to minimize the risk of side effects associated
Publikováno v:
Clinical pharmacokinetics. 39
The aim of these studies was to compare the pharmacokinetics of inhaled fluticasone propionate (FP) after repeated administration via the Diskus or Diskhaler dry powder inhalers (DPIs) to patients with mild-to-moderate asthma.Both studies evaluated t
Autor:
William S. Silvers, Stuart M. Harding, Alison Brown, Michael E Ruff, Steven W Weinstein, D. Clements, David S. Pearlman, Karen W. House, Susan P. Duke, Craig LaForce
Publikováno v:
Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology. 85(5)
Background Flovent Diskus is a powder formulation of the inhaled corticosteroid fluticasone propionate (FP) delivered via a breath-actuated, multidose inhaler. Objective To determine the efficacy and safety of dry powder FP administered once or twice
Autor:
Stuart M. Harding, Zev M. Munk, James Grady, Anthony Rooklin, Barbara A. Prillaman, James Wolfe, Anne L. Stevens, Susan P. Duke
Publikováno v:
The Journal of allergy and clinical immunology. 105(6 Pt 1)
Background: There are limited published data regarding the efficacy of once- versus twice-daily administration of flutica-sone propionate. Objective: Our purpose was to evaluate the effectiveness of fluticasone propionate powder 200 μg/d administere
Publikováno v:
Journal of Allergy and Clinical Immunology. 105:S17